Hydrocloroquine__friend_or_foe_against_COVID__1_.docx Hydroxychloroquine Efficacy and S

Document Content and Description Below

Hydrocloroquine__friend_or_foe_against_COVID__1_.docx Hydroxychloroquine Efficacy and Safety Concerns in the Treatment of COVID-19 Grand Canyon University: BIO-317V Abstract Since the World Heal... th Organization (WHO) declared the SARS-C0-V2, otherwise known as COVID-19, a pandemic, a fervent search for a therapeutic treatment was initiated. Countries outside the United States where incidences of the virus were prevalent initiated limited studies on the use of Hydroxychloroquine (HCG) to shorten the duration of the virus and to decrease mortality. Based on the results of those studies,HCQ was approved by the FDA to be utilized as an emergent treatment for COVID. Being a novel virus, the course of action the virus takes on the body is unknown but seemed to be like other SARS. Previous and ongoing studies involving the effects of the virus on patients in relation to age, gender, comorbidities and other factors are being reviewed to see if HCQ can be used safely in all patients despite it's proven adverse cardiovascular complication including prolonged QT intervals which is one of many serious adverse cardiovascular effects identified with use of this therapeutic in the fight against COVID-19. This review details the outcomes of multiple studies put forward to determine if the known risks of HCQ outweigh any benefits in becoming an approved therapeutic against that can be prescribed to all patients who are diagnosed with the COVID-19 virus . Introduction In late 2019, an outbreak of cases of pneumonia with flu like symptoms. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .. .. . . . . . . . . . . . . . . . . . .. . . . . [Show More]

Last updated: 1 year ago

Preview 1 out of 10 pages